Pfizer's 20-valent pneumonia vaccine safe, immunogenic in Phase II

Pfizer said its pneumococcal conjugate vaccine 20vPnC (PF-06482077) was safe and led to "robust" immunogenicity in a Phase II trial to prevent invasive disease and pneumonia

Read the full 268 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE